Delving into the Latest Updates on Tarapeutics Science Inc with Synapse

Overview

Tags

Neoplasms

Hemic and Lymphatic Diseases

Congenital Disorders

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	6
Hemic and Lymphatic Diseases	3
Immune System Diseases	1
Endocrinology and Metabolic Disease	1
Infectious Diseases	1

Top 5 Drug Type	Count

Small molecule drug	6

Top 5 Target	Count

FLT3(Tyrosine-protein kinase receptor FLT3)	1
CLK2 x CLK3 x DYRK1A x DYRK1B	1
RAS x Raf kinase	1
CDK9(Cyclin-dependent kinase 9)	1
EZH2(Histone-lysine N-methyltransferase EZH2)	1

主要目的：评估中国健康受试者空腹及餐后状态下单次口服TR115片在体内的血药浓度及主要药代动力学参数，评价食物对TR115片的影响。次要目的：评价中国健康受试者空腹和餐后状态下口服TR115片的安全性。评价中国健康受试者单次口服TR115片1200mg对QT间期的影响。

[Translation]

Primary purpose: To evaluate the blood concentration and main pharmacokinetic parameters of TR115 tablets in Chinese healthy subjects after a single oral administration in fasting and postprandial state, and to evaluate the effect of food on TR115 tablets. Secondary purpose: To evaluate the safety of oral administration of TR115 tablets in Chinese healthy subjects in fasting and postprandial state. To evaluate the effect of a single oral administration of 1200mg TR115 tablets on QT interval in Chinese healthy subjects.

Start Date17 Apr 2025

Sponsor / Collaborator

Tarapeutics Science Inc

NCT05751356

/ RecruitingPhase 1

A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of TR128 in Patients With Advanced Solid Tumors

This is a open-label, 3+3 design, dose escalation and expansion, phase I study, to evaluate the safety and tolerability, and to determine the Recommended Phase II Dose (RP2D) of TR128 when administered qd in patients with advanced solid tumors. Up to 5 cohorts of 3-6 patients each will be treated in dose escalation phase of the study. One cycle is 28 days. Dose expansion phase to further evaluate the safety, tolerability and preliminary anti-tumor activity of TR128 at the RP2D.

Start Date23 Feb 2024

Sponsor / Collaborator

Tarapeutics Science Inc

CTR20230464

/ RecruitingPhase 1

TR128 治疗晚期实体瘤患者中的安全性、耐受性和药代动力学的Ⅰ期临床试验

[Translation] A Phase I clinical trial to investigate the safety, tolerability and pharmacokinetics of TR128 in patients with advanced solid tumors

评估TR128胶囊单药口服给药在晚期实体瘤患者中的安全性和耐受性，确定剂量限制性毒性（DLT）、最大耐受剂量（MTD）和II期临床试验推荐剂量（RP2D）

[Translation]

To evaluate the safety and tolerability of TR128 capsules as a single oral agent in patients with advanced solid tumors, and to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and recommended dose for Phase II clinical trials (RP2D)

Start Date05 Feb 2024

Sponsor / Collaborator

Tarapeutics Science Inc

100 Clinical Results associated with Tarapeutics Science Inc

Login to view more data

0 Patents (Medical) associated with Tarapeutics Science Inc

Login to view more data

100 Deals associated with Tarapeutics Science Inc

Login to view more data

100 Translational Medicine associated with Tarapeutics Science Inc

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 11 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

Preclinical

Phase 1 Clinical

3

1

Phase 2 Clinical

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

HYML-122 ( FLT3 )	Relapsing acute myeloid leukemia More	Phase 2
TR115 ( EZH2 )	Recurrent Non-Hodgkin Lymphoma More	Phase 1
TR-64	Advanced Malignant Solid Neoplasm More	Phase 1
TR128 ( RAS x Raf kinase )	Advanced Malignant Solid Neoplasm More	Phase 1
TR-412 ( CLK2 x CLK3 x DYRK1A x DYRK1B )	Acute Myeloid Leukemia More	Preclinical